Novo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell

Companies looking to push the limits of artificial intelligence in healthcare are heading to Utah, where the state is giving them flexibility to use the

The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.

Jazz’s biliary tract cancer drug Ziihera and Lilly’s Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.

The bleak European approval potential for Soleno Therapeutics’ genetic obesity drug essentially forced the US drugmaker to sell itself for less than it was once